Literature DB >> 11422521

TNFalpha and IL-6 are mediators in the blistering process of pemphigus.

E López-Robles1, E Avalos-Díaz, E Vega-Memije, T Hojyo-Tomoka, R Villalobos, S Fraire, L Domíguez-Soto, R Herrera-Esparza.   

Abstract

BACKGROUND: Pemphigus is an autoimmune disease characterized by intraepidermal blisters induced by pemphigus IgG. In addition to autoantibodies, molecular mechanisms involved in acantholysis remain largely unknown. For this reason, we address a possible role of the inflammatory cytokines IL-6 and TNFalpha in pemphigus lesions.
METHODS: Sixteen biopsies from patients with different types of pemphigus were studied by in situ hybridization using DNA fluorescent probes for IL-6 and TNFalpha mRNA.
RESULTS: Fifty-six percent of lesional biopsies exhibited cytokine gene expression, which was poorly expressed in noninvolved skin. Deposits of TNFalpha and IL-6 were products of in situ transcription at the epidermal level.
CONCLUSIONS: Inflammatory cytokine expression around the blister could play a mediator role in pemphigus lesions by increasing epithelial damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422521     DOI: 10.1046/j.1365-4362.2001.01083.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  19 in total

1.  Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus.

Authors:  Rosangela Soares Chriguer; Ana Maria Roselino; Margaret de Castro
Journal:  J Clin Immunol       Date:  2012-03-10       Impact factor: 8.317

Review 2.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus.

Authors:  Juan Arredondo; Alexander I Chernyavsky; Ali Karaouni; Sergei A Grando
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

4.  Development of pemphigus vulgaris in a patient with vitiligo and Hashimoto's thyroiditis.

Authors:  B Yalçin; E Tamer; G G Toy; P Oztas; N Alli
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

5.  Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.

Authors:  Misa Hirose; Anika Kasprick; Foteini Beltsiou; Katharina Dieckhoff Schulze; Franziska Sophine Schulze; Unni Kjsrl Samavedam; Jennifer E Hundt; Hendri H Pas; Marcel F Jonkman; Enno Schmidt; Kathrin Kalies; Detlef Zillikens; Ralf J Ludwig; Katja Bieber
Journal:  Mol Med       Date:  2016-12-20       Impact factor: 6.354

Review 6.  Novel therapies for pemphigus vulgaris: an overview.

Authors:  Oliver A Perez; Timothy Patton
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  [Gold. Effective therapy for mucosal lesions of pemphigus vulgaris].

Authors:  D Lange; F Meiss; E Fiedler; K Treiber; W C Marsch; M Fischer
Journal:  Hautarzt       Date:  2007-02       Impact factor: 0.751

Review 8.  Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.

Authors:  Francesco Caso; Luca Iaccarino; Silvano Bettio; Francesca Ometto; Luisa Costa; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 9.  The effects of immunostimulatory herbal supplements on autoimmune skin diseases.

Authors:  Christina E Bax; Srita Chakka; Josef Symon S Concha; Majid Zeidi; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2020-06-15       Impact factor: 11.527

Review 10.  Pemphigus autoimmunity: hypotheses and realities.

Authors:  Sergei A Grando
Journal:  Autoimmunity       Date:  2011-09-23       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.